The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma

Min Seok Han, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, JaeHee Cheon, Won Ho Kim, Tae Il Kim

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Existing studies suggest that metformin lowers the risk and mortality of colorectal cancer. However, the effect of metformin on the suppression and prevention of colorectal adenomas is not clear. The aim of this study was to evaluate the effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. Methods: Among 423 diabetic patients who underwent surveillance colonoscopy after resection of colorectal adenoma between 2005 and 2011, 257 patients were retrospectively reviewed. The patients were divided into two groups: one group comprising 106 patients who took metformin and another group comprising 151 patients who did not take metformin. The clinical characteristics, colorectal adenoma recurrence, and valuable factors for adenoma recurrence were analyzed. Results: At surveillance colonoscopy after colonoscopic polypectomy for adenoma, 38 patients (35.8%) exhibited colorectal adenoma among 106 patients who took metformin, compared with 85 patients (56.3%) with colorectal adenoma among 151 patients who did not take metformin (odds ratio 0.434, 95% confidence interval 0.260–0.723, P = 0.001). Multivariate Cox analysis showed that metformin was associated with decreased recurrence of colorectal adenoma (hazard ratio 0.572, 95% confidence interval 0.385–0.852, P = 0.006) in diabetic patients with previous colorectal adenoma. The cumulative probability of colorectal adenoma recurrence was significantly lower in the metformin group than in the non-metformin group (P = 0.001). Conclusion: Metformin use in diabetic patients with previous colorectal adenoma is associated with a lower risk of colorectal adenoma recurrence.

Original languageEnglish
Pages (from-to)1223-1226
Number of pages4
JournalInternational Journal of Colorectal Disease
Volume32
Issue number8
DOIs
Publication statusPublished - 2017 Aug 1

Fingerprint

Metformin
Adenoma
Recurrence
Colonoscopy
Confidence Intervals
Colorectal Neoplasms

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Han, Min Seok ; Lee, Hyun Jung ; Park, Soo Jung ; Hong, Sung Pil ; Cheon, JaeHee ; Kim, Won Ho ; Kim, Tae Il. / The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. In: International Journal of Colorectal Disease. 2017 ; Vol. 32, No. 8. pp. 1223-1226.
@article{f06faafb36034838a2b9575de5bc78c6,
title = "The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma",
abstract = "Purpose: Existing studies suggest that metformin lowers the risk and mortality of colorectal cancer. However, the effect of metformin on the suppression and prevention of colorectal adenomas is not clear. The aim of this study was to evaluate the effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. Methods: Among 423 diabetic patients who underwent surveillance colonoscopy after resection of colorectal adenoma between 2005 and 2011, 257 patients were retrospectively reviewed. The patients were divided into two groups: one group comprising 106 patients who took metformin and another group comprising 151 patients who did not take metformin. The clinical characteristics, colorectal adenoma recurrence, and valuable factors for adenoma recurrence were analyzed. Results: At surveillance colonoscopy after colonoscopic polypectomy for adenoma, 38 patients (35.8{\%}) exhibited colorectal adenoma among 106 patients who took metformin, compared with 85 patients (56.3{\%}) with colorectal adenoma among 151 patients who did not take metformin (odds ratio 0.434, 95{\%} confidence interval 0.260–0.723, P = 0.001). Multivariate Cox analysis showed that metformin was associated with decreased recurrence of colorectal adenoma (hazard ratio 0.572, 95{\%} confidence interval 0.385–0.852, P = 0.006) in diabetic patients with previous colorectal adenoma. The cumulative probability of colorectal adenoma recurrence was significantly lower in the metformin group than in the non-metformin group (P = 0.001). Conclusion: Metformin use in diabetic patients with previous colorectal adenoma is associated with a lower risk of colorectal adenoma recurrence.",
author = "Han, {Min Seok} and Lee, {Hyun Jung} and Park, {Soo Jung} and Hong, {Sung Pil} and JaeHee Cheon and Kim, {Won Ho} and Kim, {Tae Il}",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s00384-017-2782-z",
language = "English",
volume = "32",
pages = "1223--1226",
journal = "International Journal of Colorectal Disease",
issn = "0179-1958",
publisher = "Springer Verlag",
number = "8",

}

The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. / Han, Min Seok; Lee, Hyun Jung; Park, Soo Jung; Hong, Sung Pil; Cheon, JaeHee; Kim, Won Ho; Kim, Tae Il.

In: International Journal of Colorectal Disease, Vol. 32, No. 8, 01.08.2017, p. 1223-1226.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma

AU - Han, Min Seok

AU - Lee, Hyun Jung

AU - Park, Soo Jung

AU - Hong, Sung Pil

AU - Cheon, JaeHee

AU - Kim, Won Ho

AU - Kim, Tae Il

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Purpose: Existing studies suggest that metformin lowers the risk and mortality of colorectal cancer. However, the effect of metformin on the suppression and prevention of colorectal adenomas is not clear. The aim of this study was to evaluate the effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. Methods: Among 423 diabetic patients who underwent surveillance colonoscopy after resection of colorectal adenoma between 2005 and 2011, 257 patients were retrospectively reviewed. The patients were divided into two groups: one group comprising 106 patients who took metformin and another group comprising 151 patients who did not take metformin. The clinical characteristics, colorectal adenoma recurrence, and valuable factors for adenoma recurrence were analyzed. Results: At surveillance colonoscopy after colonoscopic polypectomy for adenoma, 38 patients (35.8%) exhibited colorectal adenoma among 106 patients who took metformin, compared with 85 patients (56.3%) with colorectal adenoma among 151 patients who did not take metformin (odds ratio 0.434, 95% confidence interval 0.260–0.723, P = 0.001). Multivariate Cox analysis showed that metformin was associated with decreased recurrence of colorectal adenoma (hazard ratio 0.572, 95% confidence interval 0.385–0.852, P = 0.006) in diabetic patients with previous colorectal adenoma. The cumulative probability of colorectal adenoma recurrence was significantly lower in the metformin group than in the non-metformin group (P = 0.001). Conclusion: Metformin use in diabetic patients with previous colorectal adenoma is associated with a lower risk of colorectal adenoma recurrence.

AB - Purpose: Existing studies suggest that metformin lowers the risk and mortality of colorectal cancer. However, the effect of metformin on the suppression and prevention of colorectal adenomas is not clear. The aim of this study was to evaluate the effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. Methods: Among 423 diabetic patients who underwent surveillance colonoscopy after resection of colorectal adenoma between 2005 and 2011, 257 patients were retrospectively reviewed. The patients were divided into two groups: one group comprising 106 patients who took metformin and another group comprising 151 patients who did not take metformin. The clinical characteristics, colorectal adenoma recurrence, and valuable factors for adenoma recurrence were analyzed. Results: At surveillance colonoscopy after colonoscopic polypectomy for adenoma, 38 patients (35.8%) exhibited colorectal adenoma among 106 patients who took metformin, compared with 85 patients (56.3%) with colorectal adenoma among 151 patients who did not take metformin (odds ratio 0.434, 95% confidence interval 0.260–0.723, P = 0.001). Multivariate Cox analysis showed that metformin was associated with decreased recurrence of colorectal adenoma (hazard ratio 0.572, 95% confidence interval 0.385–0.852, P = 0.006) in diabetic patients with previous colorectal adenoma. The cumulative probability of colorectal adenoma recurrence was significantly lower in the metformin group than in the non-metformin group (P = 0.001). Conclusion: Metformin use in diabetic patients with previous colorectal adenoma is associated with a lower risk of colorectal adenoma recurrence.

UR - http://www.scopus.com/inward/record.url?scp=85013055126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013055126&partnerID=8YFLogxK

U2 - 10.1007/s00384-017-2782-z

DO - 10.1007/s00384-017-2782-z

M3 - Article

VL - 32

SP - 1223

EP - 1226

JO - International Journal of Colorectal Disease

JF - International Journal of Colorectal Disease

SN - 0179-1958

IS - 8

ER -